<DOC>
	<DOCNO>NCT02427919</DOCNO>
	<brief_summary>Granulocyte Colony Stimulating Factor ( G-CSF , filgrastim ) widely use chemotherapy complicate hematological toxicity involve neutropenia . As prolonged neutropenia lead neutropenic fever due bacteremia fungal infection , use G-CSF prevents severe infectious complication various cancer patient . In acute myeloid leukemia ( AML ) , leukemic blast expect G-CSF receptor may stimulate G-CSF , refractory patient treat G-CSF salvage chemotherapy Catholic blood marrow transplantation ( BMT ) Center long time . This strategy induce prolong neutropenia lot infectious complication lead death . Although data remind u G-CSF may proliferate leukemic blast , investigator also identify several report suggest subgroup G-CSF use show acceptable CR rate improve survival outcome compare subgroup without G-CSF use . Therefore investigator try identify effect G-CSF refractory AML patient salvage chemotherapy set regard duration neutropenia admission , incidence infectious complication duration antibiotic application . Furthermore , overall response rate ( CR+CRi ) salvage chemotherapy survival outcomes calculate accord G-CSF use . Also , investigator detect G-CSF receptor use cluster differentiation 114 ( CD114 ) , analyze clinical outcome accord subgroup without use G-CSF neutropenic period .</brief_summary>
	<brief_title>Granulocyte Colony Stimulating Factor ( G-CSF ) After Salvage Chemotherapy Refractory AML</brief_title>
	<detailed_description>Patients treat mitoxantrone etoposide cytarabine . Patients randomly divide accord usage G-CSF . Subgroup G-CSF treat G-CSF 7~10 day post-chemotherapy , blast disappear peripheral blood . Subgroup without G-CSF observe 25~28 day post-chemotherapy . If blood count recover , investigator perform bone marrow biopsy identify status bone marrow . After , G-CSF apply blast observe peripheral blood bone marrow . When absolute neutrophil count recover evidence infectious complication , patient discharge safely hospital .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0~2 AML remission failure standard chemotherapy Stable liver renal function ( = &lt; Upper normal limit ( UNL ) x 2.5 ) Stable heart lung function ( Ejection Fraction ( EF ) &gt; 45 % , Forced expiratory volume one second ( FEV1 ) &gt; 40 % ) Acute promyelocytic leukemia Central nervous system ( CNS ) involvement Uncontrolled bleeding Uncontrolled infectious complication Pregnancy , Breast feed Significant cardiovascular disease within 6 month Significant organ failure ( &gt; UNL x 2.5 )</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>G-CSF</keyword>
	<keyword>G-CSF receptor</keyword>
	<keyword>AML</keyword>
	<keyword>refractory AML</keyword>
	<keyword>Neutropenic fever</keyword>
	<keyword>salvage chemotherapy</keyword>
</DOC>